Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL

Binu K Sasi, PhD, Sven Turkalj, BS, Hilal Kalkan, BS, Fabiola Porro, MS, Engin Bojnik, PhD, Beata Pyrzynska, PhD, Abdessamad Zerrouqi, PhD, Malgorzata Bobrowicz, PhD, Magdalena Winiarska, PhD, Valdemar Priebe, MS, Francesco Bertoni, MD, Larry Mansouri, PhD, Richard Rosenquist, MD PhD, Dimitar G Efremov, MD PhD

Blood (2018) 132 (Supplement 1): 2860.

https://doi.org/10.1182/blood-2018-99-118120

Published: 2018

Journal Articles

The Bcl-2 BH4 Antagonist Bda-366 Induces Apoptosis in CLL and DLBCL Cells through a Bcl-2 Independent Mechanism

Binu K Sasi, PhD, Tamara Vervloessem, PhD, Stefania Gobessi, PhD, Idanna Innocenti, MD, Luca Laurenti, Geert Bultynck, PhD, Dimitar G Efremov, MD PhD

Blood (2016) 128 (22): 2014.

https://doi.org/10.1182/blood.V128.22.2014.2014

Published: 2016

Journal Articles

FcμR Triggering Activates BCR Signaling Pathways and Increases Survival of CLL Cells

Stefania Gobessi, PhD, Binu K Sasi, PhD, Gabriele Pozzato, MD, Idanna Innocenti, MD, Luca Laurenti, Dimitar G Efremov, MD PhD

Blood (2016) 128 (22): 2015.

https://doi.org/10.1182/blood.V128.22.2015.2015

Published: 2016

Journal Articles

BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199

Kamil Bojarczuk, Binu K. Sasi, Stefania Gobessi, Idanna Innocenti, Gabriele Pozzato, Luca Laurenti, Dimitar G. Efremov

Blood (2016) 127 (25): 3192–3201.

https://doi.org/10.1182/blood-2015-10-675009

Published: 2016

Includes: Supplemental data

Journal Articles

Inhibition of SYK More Effectively Overcomes MCL-1 Mediated ABT-199 Resistance of BCR-Stimulated CLL Cells Than Inhibition of BTK or PI3Kdelta

Kamil Bojarczuk, PhD, Binu K Sasi, PhD, Stefania Gobessi, PhD, Idanna Innocenti, MD, Luca Laurenti, MD, Dimitar G Efremov, MD PhD

Blood (2015) 126 (23): 489.

https://doi.org/10.1182/blood.V126.23.489.489

Published: 2015

Journal Articles

Serum IgM Activates BCR Signaling Pathways and Increases Survival of Chronic Lymphocytic Leukemia B Cells

Stefania Gobessi, PhD, Binu K Sasi, PhD, Luca Laurenti, MD, Dimitar G Efremov, MD PhD

Blood (2015) 126 (23): 4131.

https://doi.org/10.1182/blood.V126.23.4131.4131

Published: 2015

NARROW

SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL

The Bcl-2 BH4 Antagonist Bda-366 Induces Apoptosis in CLL and DLBCL Cells through a Bcl-2 Independent Mechanism

FcμR Triggering Activates BCR Signaling Pathways and Increases Survival of CLL Cells

BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199

Inhibition of SYK More Effectively Overcomes MCL-1 Mediated ABT-199 Resistance of BCR-Stimulated CLL Cells Than Inhibition of BTK or PI3Kdelta

Serum IgM Activates BCR Signaling Pathways and Increases Survival of Chronic Lymphocytic Leukemia B Cells

Email alerts

ASH Publications

American Society of Hematology

SHP1 Deficiency Is Responsible for the Constitutive Activation of the BCR Pathway in GCB DLBCL

The Bcl-2 BH4 Antagonist Bda-366 Induces Apoptosis in CLL and DLBCL Cells through a Bcl-2 Independent Mechanism

FcμR Triggering Activates BCR Signaling Pathways and Increases Survival of CLL Cells

BCR signaling inhibitors differ in their ability to overcome Mcl-1–mediated resistance of CLL B cells to ABT-199

Inhibition of SYK More Effectively Overcomes MCL-1 Mediated ABT-199 Resistance of BCR-Stimulated CLL Cells Than Inhibition of BTK or PI3Kdelta

Serum IgM Activates BCR Signaling Pathways and Increases Survival of Chronic Lymphocytic Leukemia B Cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only